Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements

Journal of Cellular Physiology

Volumn 214, Issue 2, 2008, Pages 295-300

  Tonini, Tiziana ^a   D'Andrilli, Giuseppina ^a   Fucito, Alfredo ^a   Gaspa, Leonardo ^b   Bagella, Luigi ^a,b  

^a Temple University   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN; PROTEIN EZH2; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; HISTONE DEACETYLASES; HUMANS; MALE; MODELS, GENETIC; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEINS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSCRIPTION FACTORS;

EID: 37349036525     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21241     Document Type: Review

References (114)

1. Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M. 1997a. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev 11:226-240.
2. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. 1997b. Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 15:899-910.
3. Anwar F, Emond MJ, Schmidt RA, Hwang HC. Bronner MP. 2000. Retinoblastoma expression in thyroid neoplasms. Mod Pathol 13:562-569.
4. Azechi H, Nishida N, Fukuda Y, Nishimura T, Minata M, Katsuma H, Kuno M, Ito T, Komeca T, Kita R, Takahashi R, Nakao K. 2001. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 60:346-354.
5. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. 2006. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268-273.
6. Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi MG, De Luca A, Claudio PP, Giordano A. 2007. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 26:1829-1839.
7. Baldi A, Esposito V, De Luca A, Fu Y, Meoli I, Giordano GG, Caputi M, Baldi F, Giordano A. 1997. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 3:1691-1697.
8. Baldi A, Esposito V, De Luca A, Howard CM, Mazzarella G, Baldi F, Caputi M, Giordano A. 1996. Differential expression of the retinoblastoma gene family members pRb/p 105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 2:1239-124S.
9. Bardos JI, Saurin AJ, Tissot C, Duprez E, Freemont PS. 2000. HPC3 is a new human polycomb orthologue that interacts and associates with RING1 and Bmi1 and has transcriptional repression properties. J Biol Chem 275:28785-28792.
10. Bartek J, Bartkova J, Lukas J. 1997. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 237:1-6.
11. Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2:S4-S11.
12. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. 2003. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 22:5323-5335.
13. Brambilla E, Moro D, Gazzeri S, Brambilla C. 1999. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 188:351-360.
14. Cardoso C, Timsit S, Villard L, Khrestehatisky M, Fontes M, Colleaux L. 1998. Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet 7:679-684.
15. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Caiabretta B, Giordano A. 1994. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54:5556-5560.
16. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Hicheli P, Caputi M, Giordano GG, Giordano A. 2000. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 60:372-382.
17. Claudio PP, Russo G, Kumar CA, Minimo C, Farina A, Tutton S, Nuzzo G, Giuliante F, Angeloni G, Maria V, Vecchio FM, Campli CD, Giordano A. 2004. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: Their clinical significance. Clin Cancer Res 10:3509-3517.
18. Claudio PP, Zamparelli A, Garcia FU, Claudio L, Ammirati G, Farina A, Bovicelli A, Russo G, Giordano GG, McGinnis DE, Giordano A, Cardi G. 2002. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67(MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 8:1808-1815.
19. Cohen KJ, Hanna JS, Prescott JE, Dang CV. 1996. Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol 16:5527-5535.
20. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. 2006. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12:1168-1174.
21. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. 1992. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251-1256.
22. D'Andrilli G, Masciullo V, Bagella L, Tonini T, Minimo C, Zannoni GF, Giuntoli RL 2nd, Carlson JA Jr, Soprano DR, Soprano KJ, Scambia G, Giordano A. 2004. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin Cancer Res 10:3098-3103.
23. Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC. 2001. Linking the Rb and polycomb pathways. Mol Cell 8:557-569.
24. de Jong JS, van Diest PJ, Michalides RJ, van der Valk P, Meijer CJ, Baak JP. 1998. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. Mol Pathol 51:30-34.
25. De Luca A, MacLachlan TK, Bagella L, Dean C, Howard CM, Claudio PP, Baldi A, Khalili K, Giordano A. 1997. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J Biol Chem 272:20971-20974.
26. Ding L, Kleer CG. 2006. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66:9352-9355.
27. Dong Y, Walsh MD, McGuckin MA, Cummings MC, Gabrielli BG, Wright GR, Hurst T, Khoo SK, Parsons PG. 1997. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74:407-415.
28. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ, Raaphorst FM. 2004. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 164:873-881.
29. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262.
30. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. 1998. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci U S A 95:10493-10498.
31. Ferreira R, Naguibneva I, Mathieu M, Ait-Si-Ali S, Robin P, Pritchard LL, Harel-Bellan A. 2001. Cell cycle-dependent recruitment of HDAC-1 correlates with deacetylation of histone H4 on an Rb-E2F target promoter. EMBO Rep 2:794-799.
32. Glozak MA, Sengupta N, Zhang X, Seto E. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363:15-23.
33. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. 2004. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086.
34. Harbour JW, Dean DC. 2000a. Chromatin remodeling and Rb activity. Curr Opin Cell Biol 12:685-689.
35. Harbour JW, Dean DC. 2000b. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2:E65-E67.
36. Hinton DR, Hahn JA, Weiss MH, Couldwell WT. 1998. Loss of Rb expression in an ACTH-secreting pituitary carcinoma. Cancer Lett 126:209-214.
37. Hobert O, Jallal B, Ullrich A. 1996. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 16:3066-3073.
38. Hong L, Schroth GP, Matthews HR, Yau P, Bradbury EM. 1993. Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 268:305-314.
39. Howard CM, Claudio PP, Gallia GL, Gordon J, Giordano GG, Hauck WW, Khalili K, Giordano A. 1998. Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J Natl Cancer Inst 90:1451-1460.
40. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. 2000. Clinical significance of retinoblastoma protein (pRB) expression in esophageal squamous cell carcinoma. J Surg Oncol 73:104-108.
41. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. 1999a. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168.
42. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. 1999b. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678-2690.
43. Jares P, Rey MJ, Fernandez PL, Campo E, Nadal A, Munoz M, Mallofre C, Muntane J, Nayach I, Estape J, Cardesa A. 1997. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: Correlation with tumour proliferation and oestrogen receptor status. J Pathol 182:160-166.
44. 1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 33:877-883.
45. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606-11611.
46. 1/S transition and S-phase progression. Genes Dev 12:2278-2292.
47. Knudsen ES, Wang JY. 1996. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271:8313-8320.
48. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. 2000. RB-dependent S-phase response to DNA damage. Mol Cell Bioi 20:7751-7763.
49. Korkolopoulou PA, Angelopoulou MK, Kontopidou FN, Patsouris EV, Christodoulou PN, Kittas CN, Davaris P, Pangalis GA. 2001. Retinoblastoma gene product and P21 (WAF1, CIP1) protein expression in non Hodgkin's lymphomas: A multivariate survival analysis. Leuk Lymphoma 40:647-658.
50. Kornberg RD, Lorch Y. 1999a. Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev 9:148-151.
51. Kornberg RD, Lorch Y. 1999b. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98:285-294.
52. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. 1998. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: A prospective study. Clin Cancer Res 4:1955-1963.
53. Lee C, Chang JH, Lee HS, Cho Y. 2002. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes Dev 16:3199-3212.
54. Lee C, Cho Y. 2002. Interactions of SV40 large T antigen and other viral proteins with retinoblastoma tumour suppressor. Rev Med Virol 12:81-92.
55. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. 2003. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200:39-46.
56. Leoncini L, Bellan C, Cossu A, Claudio PP, Lazzi S, Cinti C, Cevenini G, Megha T, Laurini L, Luzi P, Orcioni GF, Piccioli M, Pileri S, Giardino C, Tosi P, Giordano A. 1999. Retinoblastoma-related p107 and pRb2/p 130 proteins in malignant lymphomas: Distinct mechanisms of cell growth control. Clin Cancer Res 5:4065-4072.
57. Lerma E, Esteller M, Herman JG, Prat J. 2002. Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol 33:1120-1125.
58. 1 arrest: Molecular mechanisms and implications for oncogenesis. Oncogene 18:3930-3935.
59. Lundberg AS, Weinberg RA. 1998. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753-761.
60. Luo RX, Postigo AA, Dean DC. 1998. Rb interacts with histone deacetylase to repress transcription. Cell 92:463-473.
61. Macaiuso M, Cinti C, Russo G, Russo A, Giordano A. 2003. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene 22:3511-3517.
62. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A. 1998. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601-605.
63. Massaro-Giordano M, Baldi G, De Luca A, Baldi A, Giordano A. 1999. Differential expression of the retinoblastoma gene family members in choroidal melanoma: Prognostic significance. Clin Cancer Res 5:1455-1458.
64. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, Persiani R, Giordano A, Claudio PP. 2007. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 210:183-191.
65. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, Caviglia R, Pollice L, Gabbrielli A, Giordano A, Claudio PP. 2006. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21 waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol 207:512-519.
66. Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM, Loning T. 2001. Expression of Rb2/p130 in breast and endometrial cancer: Correlations with hormone receptor status. Br J Cancer 85:546-551.
67. Mittnacht S. 1998. Control of pRB phosphorylation. Curr Opin Genet Dev 8:21-27.
68. MobergK, Starz MA, Lees JA. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16:1436-1449.
69. Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y, Matsumura T. 2000. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 160:3-8.
70. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, Sakaki T. 1997. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 80:242-249.
71. Nevins JR. 1998. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 9:585-593.
72. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Geary M, Jenuwein T, Herrera RE, Kouzarides T. 2001. Rb targets histone H3 methylation and HP1 to promoters. Nature 412:561-565.
73. Omura K, Nagasato A, Kanehira E, Kinsen H, Amaya S, Kimura K, Kajita T, Nozaki Y, Mizukami Y, Nonomura A, Watanabe Y. 1997. Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma. J Clin Oncol 15:3458-3463.
74. Otte AP, Kwaks TH. 2003. Gene repression by Polycomb group protein complexes: A distinct complex for every occasion? Curr Opin Genet Dev 13:448-454.
75. Paggi MG, Baldi A, Bonetto F, Giordano A. 1996. Retinoblastoma protein family in cell cycle and cancer: A review. J Cell Biochem 62:418-430.
76. Pazin MJ, Kadonaga JT. 1997. What's up and down with histone deacetylation and transcription? Cell 89:325-328.
77. Pirrotta V, 1997. PcG complexes and chromatin silencing. Curr Opin Genet Dev 7:249-258.
78. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. 2000. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 157:709-715.
79. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. 2005. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11:8570-8576.
80. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. 2003. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661-668.
81. Ross JF, Naar A, Cam H, Gregory R, Dynlacht BD. 2001. Active repression and E2F inhibition by pRB are biochemically distinguishable. Genes Dev 15:392-397.
82. Russo G, Zamparelli A, Howard CM, Minimo C, Bellan C, Carillo G, Califano L, Leoncini L, Giordano A. Claudio PP. 2005. Expression of cell cycle-regulated proteins pRB2/p130, p107, E2F4, p27, and pCNA in salivary gland tumors: Prognostic and diagnostic implications. Clin Cancer Res 11:3265-3273.
83. Satijn DP, Hamer KM, den Blaauwen J, Otte AP. 2001. The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol 21:1360-1369.
84. Satijn DP, Otte AP. 1999. RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol 19:57-68.
85. Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. 2004. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24:679-685.
86. Sauerbrey A, Stammler G, Zintl F, Volm M. 1998. Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia. Leuk Lymphoma 28:275-283.
87. Sellers WR, Loda M. 2002. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell 2:349-350.
88. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
89. Shilatifard A. 2006. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem 75:243-269.
90. Slansky JE, Farnham PJ. 1996. Introduction to the E2F family: Protein structure and gene regulation. Curr Top Microbiol Immunol 208:1-30.
91. 1 cell state. Mol Cell Biol 16:6965-6976.
92. Stiegler P, De Luca A, Bagella L, Giordano A. 1998. The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res 58:5049-5052.
93. Struhl K. 1998. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606.
94. Susini T, Baldi F, Howard CM, Baldi A, Taddei G, Massi D, Rapi S, Savino L, Massi G, Giordano A. 1998. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol 16:1085-1093.
95. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP. 2004. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141-1149.
96. Takihara Y, Hara J. 2000. Polycomb-group genes and hematopoiesis. Int J Hematol 72:165-172.
97. Tamboli P, Amin MB, Xu HJ, Linden MD. 1998. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 11:247-252.
98. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. 2007. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050-1063.
99. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, Matsuda H. 1998. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 79:111-115.
100. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. 2004. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23:5759-5769.
101. Taunton J, Hassig CA, Schreiber SL. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411.
102. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. 1997. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158:131-137.
103. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. 2004. Ezh2 reduces the ability of HDAC1-dependent pRb2/p 130 transcriptional repression of cyclin A. Oncogene 23:4930-4937.
104. Turner BM. 1991. Histone acetylation and control of gene expression. J Cell Sci 99:13-20.
105. van der Vlag J, Otte AP. 1999. Transcriptional repression mediated bythe human polycomb-group protein EED involves histone deacetylation. Nat Genet 23:474-478.
106. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Msijer CJ. 2001. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896-3901.
107. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. 199 I. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65:737-752.
108. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D. 2001. Transcriptioral repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 21:6484-6494.
109. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629.
110. Wang J, Mager J, Schnedier E, Magnuson T. 2002. The mouse PcG gene eed is required for Hox gene repression and extraembryonic development. Mamm Genome 13:493-503.
111. Xiao B, Wilson JR, Gamblin SJ. 2003. SET domains and histone methylation. Curr Opin Struct Biol 13:699-705.
112. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF. 1994. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86:695-699.
113. Yamamoto K, Sonoda M, Inokuchi J, Shirasawa S, Sasazuki T. 2004. Polycomb group suppressor ofzeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2. J Biol Chem 279:401-406.
114. Zamparelli A, Masciullo V, Bovicelli A, Santini D, Ferrandina G, Minimo C, Terzano P, Costa S, Cinti C, Ceccarelli C, Mancuso S, Scambia G, Bovicelli L, Giordano A. 2001. Expression of cell-cycle-associated proteins pRB2/p130 and p27kip in vulvar squamous cell carcinomas. Hum Pathol 32:4-9.